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Age, malignancy, and cell dose had no impact on OI. The median
values for major leukocytes were; WBC: 0.7  10e3/l, T cells:
63/l, NK cells: 47/l, B cells: 0/l, CD4T cells: 42/l,
%CD4 T cells: 66%. Both the OI and OI group had com-
parable WBC, CD3, CD4 T cells, NK lymphocytes, or DC1,
DC2 subsets. Strikingly, 44% of circulating T cells were in cell
cycle (KI-67) and 10% were entering apoptosis (activated
Caspase-3), regardless of OI status. Only 16% preserved the
CD45RA/CD62L phenotype of the infused graft. We con-
clude that in lymphopenic UCBT recipients even undetectable
viral infections may induce T cell maturation towards effector
CD8 Tc1 cells as soon as 2–3 weeks after UCBT allowing early
identiﬁcation of those at risk for clinical OI (Table1).
Differences in Lymphocyte Reconstitution Between Those Who Will
Develop Opportunisitic Infections (OI) or Not
Variable
OI Median
Value
OI Median
Value P-Value
% CD8 T cells 39 28 .04
% CCR-5 T cells 85 56 .005
% CD8/CD57/CD28 6 2.8 .027
Abs
CD8/CD57/CD28 1.3 0.4 .017
% IFN T cells 35.1 12.2 .006
% CD4/IFN T cells 14 10 .017
% CD8/Perforin T cells 48 26 .019
MFI of BCL-2 in T cells 76 54 .036
Absolute values in microliter.
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FACTORS AFFECTING IMMUNOLOGIC RECOVERY AFTER NONMYELOA-
BLATIVE CONDITIONING
Baron, F.1, Piette, F.1, Maris, M.1, Storek, J.1, Metcalf, M.1,
White, K.1, Sandmaier, B.1, Maloney, D.1, Storer, B.1, Storb, R.1,
Boeckh, M.1 Fred Hutchinson Cancer Research Center, Seattle, WA.
Background/Methods: We investigated factors affecting im-
mune recovery after nonmyeloablative (NM) conditioning in 94
pts given PBSC from HLA-matched related (MRD, n  51) or
unrelated (URD, n  43) donors after 2 Gy TBI / ﬂudarabine.
Postgrafting immunosuppression (IS) consisted of mycophenolate
mofetil (MMF, given TID for 40 days followed by a 56 day taper
in URD recipients, and BID for 28 days in MRD recipients) and
cyclosporin. Univariate and multivariate analyses were performed
to determine factors affecting counts of CD4 T cells, naive CD4 T
cells, CD8 T cells, B cells, and frequency of CMV-speciﬁc CD4
T-helper cells (among CMV seropositive pts or CMV-seronega-
tive pts with CMV-seropositive donors; determined by lympho-
proliferation (CMV-CPM)) on days 30, 80, 180, and 365 after
HCT.Results: In multivariate analyses, URD recipients had lower
counts of CD4 T cells, naive CD4 T cells, CD8 T cells, and
CMV-CPM than MRD on day 30 after HCT. This delay in
CMV-speciﬁc immune reconstitution was accompanied by in-
creased frequency of CMV-reactivation (and increased use of pre-
emptive antiviral therapy [PET]) among CMV-seropositive pts or
CMV-seronegative pts with CMV sero-positive donors given
URD grafts (cumulative incidence [CI] 61%) compared with MRD
(33%) recipients the ﬁrst 100 days after HCT. This did not lead to
increased CMV disease among URD recipients (1 episode) com-
pared with MRD recipients (1 episode), demonstrating that PET
was similarly effective in preventing CMV diseases in both groups.
Higher donor age was associated with lower counts of naive CD4
T cells, suggesting that most naive CD4 T cells derived from
transplanted naive CD4 T cells rather than through neo-genera-
tion. As seen in pts given myeloablative conditioning, CMV-sero-
positive patients had higher levels of CD8 T cells after HCT.
Further, lower levels of T cells and CD34 cells in the grafts, as
well as acute GVHD, impaired immune recovery of naive CD4 T
cells and B-cells (Table 1). Conclusions: Despite similar NM
conditioning regimens, immunologic recovery was delayed among
URD recipients in comparison to MRD recipients, either because
of increased/extended postgrafting IS or the greater degrees of
antigenic disparities between donors and recipients. This resulted
in a higher incidence of CMV-infection and increased use of PET.
Other factors associated with immune recovery were donor age,
patient CMV-serostatus, number of CD34 and T cells in the graft,
as well as acute GVHD (Table 1).
Table 1. Multivariate Analyses of Factors Affecting Immune
Recovery After NM Conditioning
Cell Subset
Day
After HCT
Factor(s) Associated With
Lower Cell Subset Counts
CD4 T-cell 30 URD vs MRD (P  .06)
CD4 T-cell 80 URD vs MRD (P  .003);
High donor age
(P  .006)
CD4 T-cell 180 & 365 MRD vs URD (P  .035)
Naive CD4 T-cell 30 URD vs MRD (P < .001);
High donor age
(P  .001)
Naive CD4 T-cell 80 Low # of CD34 cells
transplanted (P  .006);
Grade II–IV acute
GVHD (P  .007)
Naive CD4 T-cell 180 & 365 High donor age
(P  .003); Pt CMV
seropositive (P  .03)
CD8 T-cell 30 URD vs MRD (P < .001)
CD8 T-cell 80 Pt CMV seronegative
(P  .018)
CD8 T-cell 180 & 365 Pt CMV seronegative
(P  .06)
B-cell 30 Low no. of CD34 cells
transplanted
(P  .022); Low # of
T-cells transplanted
(P  .039)
B-cell 80 Low no. of T-cells
transplanted
(P  .002); Grade II–IV
acute GVHD (P  .08)
B-cell 180 & 365 Grade II–IV acute GVHD
(P  .031)
CMV-
CPM† 30 URD vs MRD (P  .007)
CMV-
CPM† 80 URD vs MRD (P  .008);
Low no. of T-cells
transplanted (P  .02)
CMV-
CPM† 180 & 365 Low no. of T-cells
transplanted (P  .01)
Other factors assessed were pt age, prior chemotherapy or not,
day 28 T-cell chimerism, extensive chronic GVHD; contin-
uous linear variable; †analyses restricted to CMV seropositive
pt or donor.
240
SIGNIFICANCE OF LYMPHOCYTE CONTRIBUTION POST PROCESSING IN
CORD BLOOD TRANSPLANTATION
Wofford, J.D.1, Regan, D.M.1, Alonso, J.M.F.1, Creer, M.H.2 1. St.
Louis Cord Blood Bank at SSM Cardinal Glennon Children’s Hospital,
St. Louis, MO; 2. St. Louis University, St. Louis, MO.
In cord blood transplantation, engrafting cell populations include
hematopoietic stem/progenitor cells. Naive and antigen-speciﬁc T
and B cells mediate protective immune responses as well as graft-
versus-host reactions. Total Nucleated Cell Dose (TNC) has con-
sistently been shown to correlate with recipient outcome. A major
complication, including death, in post transplant recovery is infec-
tion. In this preliminary analysis, we attempt to determine the
signiﬁcance of the lymphocyte contribution with regard to infec-
tion control post cord blood infusion. The outcomes of 318 single
cord blood unit transplants have been evaluated. Recipients were
assigned to groups based on the percentage of lymphocytes post
processing. The overall mean was 30%. Group 1 consists of recip-
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